C Diff Treatment

C. diff is a horrible disease that can cause significant morbidity, can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but we can do better.

Background In the last two decades, a significant increase in the number of Clostridioides difficile infection (CDI) cases has been observed. It is understandable to attempt to determine the factors that can predict the severity of the course of the infection and identify patients at risk of death. This study aimed to analyze the factors affecting the incidence and mortality of CDI in inpatient treatment at the University Clinical Hospital in Wrocław in 2016–2018. Methods Statistical analysis of data obtained from patients’ medical records was performed. Only patients with symptoms of infection and infection confirmed by laboratory tests were enrolled in the study. When analyzing the number of deaths, only adult patients who died in hospital wards were included. The quantitative data including laboratory tests, used antibiotics and Nutritional Risk Screening (NRS) were assessed. Also, the qualitative data such as sex, year of hospitalization, occurrence of diarrhoea on admission to the hospital, presence of additional diseases, as wee ad the use of antibacterial drugs or proton pump blockers and ranitidine during hospitalization were analyzed. Results A total of 319 adult CDI patients (178 women and 141 men) were enrolled of which 80 people died (50 women and 30 men). The mean age of the patients was 72.08 ± 16.74 years. Over the entire period studied, the morbidity was 174 cases per 100,000 hospitalizations while mortality was 25.08%. The group of deceased patients was characterized by: older age (by 9.24 years), longer duration of hospitalization (by 10 days), reduced albumin levels (Rho = -0.235, p

Clostridium difficile infection has several known risk factors, but opioid use is not currently recognized as one of them. In a new study, researchers evaluated the effects of opioid use on outcomes among inpatients with C difficile infection.

In this study, the morbidity was lower, but mortality was higher compared to similar hospitals in Poland. CDI patients were characterized by older age, multimorbidity, extended hospitalization, and the use of broad-spectrum antibiotics. Risk factors for death included advanced age, prolonged hospita …

Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for patient dosing and clinical management strategies associated with concurrent therapy.

Clostridioides difficile is endemic in the intestinal tract of healthy people. However, it is responsible for many healthcare-associated infections, such as ...

While combinations of probiotics with antibiotics have exhibited beneficial and adverse effects in the treatment of Clostridium difficile infection (CDI), no...

SUMMARYClostridioides difficile infection (CDI) is one of the major issues in nosocomial infections. This bacterium is constantly evolving and poses complex challenges for clinicians, often encountered in real-life scenarios. In the face of CDI, we are ...

Toxic megacolon denotes an abrupt non-obstructive distension of the colon, accompanied by systemic signs of toxicity. Mortality rates can soar as high as 7.9%. While primarily linked with chronic bowel conditions, the incidence attributed to Clostridioides difficile has surged due to the indi …

The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.

Clostridioides difficile infection (CDI) is a significant public health challenge in the developed world. Although previously CDI was primarily a health care-acquired infection, there are now rising numbers of community-acquired cases in patients without traditional risk factors, such as antibiotic …

Treating Helicobacter pylori and Clostridioides difficile coinfection presents a challenging clinical dilemma. Treating H. pylori may increase the risk of C. difficile, and antibiotics generally have been shown to increase the risk of C. difficile infection/recurre …

Pune, Feb. 19, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Clostridium Difficile Infections...

We present a case of tubo-ovarian abscess (TOA) caused by Clostridioides difficile (CD) in a 43-year-old female. Despite lacking a history of sexually transmitted diseases, the patient had undergone paraovarian cystectomy nine months before admission. Transvaginal ultrasonography performed eight mon …

Clostridioides difficile is a leading cause of healthcare-associated infections, causing billions of economic losses every year. Its symptoms range from mild diarrhea to life-threatening damage to the colon. Transmission and recurrence of C. difficile infection (CDI) are mediated by th …

Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.

Feldman, who previously had C. diff, urges individuals to begin having conversations to help remove the stigma of the disease and raise awareness of its prevalence.

We have started to understand the critical components of the gut microbiome that prevent C. difficile expansion, and with that knowledge comes the potential to block ...

Minnie Hatch was in her late teens when she was diagnosed with the infection. Since then, she has had recurrent episodes and dealt with care challenges along the way.

Check out the latest studies, management strategies, patient advocacy, and other important news involving this condition.

Fidaxomicin treated patients had statistically increased odds of rCDI. Compared to other treatments, fidaxomicin was inferior to metronidazole for rCDI in our cohort;Hypervirulent C. difficile was not associated with death.Vancomycin resistance of C. difficile statistically decreased, …

Aberrant changes in the gut microbiota are implicated in many diseases, including inflammatory bowel disease (IBD). Gut microbes produce diverse metabolites that can shape the immune system and impact the intestinal barrier integrity, indicating that microbe-mediated modulation may be a promising st …

PARSIPPANY, N.J.--(BUSINESS WIRE)--May 20, 2024--

Gastrointestinal infections are still responsible for around 60% of the infectious diseases that must be reported in Germany and are probably among the most common gastroenterological diseases. The main therapy for gastrointestinal infections remains oral fluid replacement. The recommendations for …

In the treatment of CDI, we showed that real-world use of fidaxomicin is associated with lower risk of a composite endpoint of treatment failure.

Cure rates associated with vancomycin for Clostridioides difficile infection have declined from nearly 100% in the early 2000s to 70% in recent years.

Antimicrobial stewardship to reduce multidrug resistance and opportunistic Clostridioides difficile infection (CDI) could also guide shorter treatment.

Pune, Feb. 19, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Clostridium Difficile Infections...

Clostridioides difficile (C. difficile) is one of the leading causes of healthcare-associated infections worldwide. The increasing incidence of strains resistant to currently available therapies highlights the need for alternative treatment options with a novel mode of action. Oxazolid …

Dennis Petragnani has battled gastrointestinal issues for years, and he shares what he sees as the transformation of change in the public and medical community talking about C diff and therapies around it, and the kinship with people he has met through the Peggy Lillis Foundation.